Charupong Saengboonmee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7887473/publications.pdf

Version: 2024-02-01

1305906 1255698 15 428 13 8 g-index citations h-index papers 15 15 15 973 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Lepromatous leprosy with a suspected 30-year incubation period: A case report of a practically eradicated area. Journal of Taibah University Medical Sciences, 2022, 17, 602-605.	0.5	1
2	Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication. Canadian Journal of Diabetes, 2021, 45, 282-290.	0.4	8
3	High glucose upregulates FOXM1 expression via EGFR/STAT3 dependent activation to promote progression of cholangiocarcinoma. Life Sciences, 2021, 271, 119114.	2.0	12
4	Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 1047-1059.	1.4	8
5	High glucose: an emerging association between diabetes mellitus and cancer progression. Journal of Molecular Medicine, 2021, 99, 1175-1193.	1.7	38
6	High Glucose Induced Upregulation of Cyclin a Associating with a Short Survival of Patients with Cholangiocarcinoma: A Potential Target for Treatment of Patients with Diabetes Mellitus. Nutrition and Cancer, 2021, , 1-11.	0.9	1
7	Repurposing Metformin for Cancer Treatment: A Great Challenge of a Promising Drug. Anticancer Research, 2021, 41, 5913-5918.	0.5	11
8	NF- $\hat{\mathbb{P}}$ B and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells. Life Sciences, 2020, 262, 118548.	2.0	9
9	Overexpression of HexCer and LacCer containing 2-hydroxylated fatty acids in cholangiocarcinoma and the association of the increase of LacCer (d18:1-h23:0) with shorter survival of the patients. Glycoconjugate Journal, 2019, 36, 103-111.	1.4	12
10	Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Review of Anticancer Therapy, 2018, 18, 579-592.	1.1	10
11	High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Scientific Reports, 2017, 7, 43842.	1.6	75
12	Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-Ä,B. Anticancer Research, 2017, 37, 115-124.	0.5	48
13	High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation. Scientific Reports, 2016, 6, 18995.	1.6	58
14	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Reports, 2016, 14, 907-919.	2.9	107
15	Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma. Cancer Epidemiology, 2015, 39, 274-278.	0.8	30